SCHEMBL719334

SCHEMBL719334

COCc1nn(-c2cccc(OC)c2)cc1C(O)C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
TP53 P04637 1/20 0.37
RAB9A P51151 1/20 0.37
CCR1 P32246 1/20 0.36
ALDH1A1 P00352 2/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719184 0.92 PDE4A (0.43) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL716549 0.89 RAB9A (0.40) SMN1; SMN2RAB9AALDH1A1IDO1TDO2
SCHEMBL717837 0.89 RAB9A (0.39) SMN1; SMN2RAB9AALDH1A1IDO1TDO2
SCHEMBL717877 0.86 BCHE (0.42) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL720040 0.84 NOTUM (0.46) BCHESMN1; SMN2TSHRHSD17B10PDE4A
SCHEMBL718338 0.84 BCHE (0.41) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL716753 0.81 GCGR (0.38) ALDH1A1IDO1TDO2KDM4ERXRA
SCHEMBL719683 0.79 BCHE (0.42) BCHECYP1A2CYP3A4CYP2C19SMN1; SMN2
SCHEMBL721464 0.79 KDM4E (0.42) SMN1; SMN2RAB9AALDH1A1IDO1TDO2
SCHEMBL718337 0.77 DRD3 (0.36) CYP1A2CYP3A4CYP2C19TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP BCHE 1649/4885CYP1A2 774/4885CYP3A4 834/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP BCHE 1649/4885CYP1A2 774/4885CYP3A4 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.